CA2857046A1 - Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof - Google Patents

Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof Download PDF

Info

Publication number
CA2857046A1
CA2857046A1 CA2857046A CA2857046A CA2857046A1 CA 2857046 A1 CA2857046 A1 CA 2857046A1 CA 2857046 A CA2857046 A CA 2857046A CA 2857046 A CA2857046 A CA 2857046A CA 2857046 A1 CA2857046 A1 CA 2857046A1
Authority
CA
Canada
Prior art keywords
hetre
antimicrobial composition
units
dgla
composition comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2857046A
Other languages
English (en)
French (fr)
Inventor
Jonathan Rowe
David Coughlan
Mehar Manku
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DS Biopharma Ltd
Original Assignee
DS Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DS Biopharma Ltd filed Critical DS Biopharma Ltd
Publication of CA2857046A1 publication Critical patent/CA2857046A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2857046A 2012-01-26 2013-01-25 Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof Abandoned CA2857046A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261591036P 2012-01-26 2012-01-26
US61/591,036 2012-01-26
US13/478,990 US20120264705A1 (en) 2012-01-26 2012-05-23 Antimicrobial compositions comprising 15-hetre and methods of use thereof
US13/478,990 2012-05-23
PCT/US2013/023201 WO2013112876A1 (en) 2012-01-26 2013-01-25 Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof

Publications (1)

Publication Number Publication Date
CA2857046A1 true CA2857046A1 (en) 2013-08-01

Family

ID=47006834

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2857046A Abandoned CA2857046A1 (en) 2012-01-26 2013-01-25 Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof

Country Status (16)

Country Link
US (2) US20120264705A1 (cg-RX-API-DMAC7.html)
EP (1) EP2806868A4 (cg-RX-API-DMAC7.html)
JP (3) JP6557009B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140117379A (cg-RX-API-DMAC7.html)
CN (1) CN104114166A (cg-RX-API-DMAC7.html)
AU (1) AU2013211982A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014018421A8 (cg-RX-API-DMAC7.html)
CA (1) CA2857046A1 (cg-RX-API-DMAC7.html)
HK (1) HK1198921A1 (cg-RX-API-DMAC7.html)
IL (1) IL232777A0 (cg-RX-API-DMAC7.html)
MX (1) MX2014006947A (cg-RX-API-DMAC7.html)
PH (1) PH12014501693A1 (cg-RX-API-DMAC7.html)
RU (1) RU2014134720A (cg-RX-API-DMAC7.html)
SG (1) SG11201404088TA (cg-RX-API-DMAC7.html)
WO (1) WO2013112876A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201403948B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US9855236B2 (en) 2011-10-19 2018-01-02 Ds Biopharma Limited Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof
US8293790B2 (en) * 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
RU2014119948A (ru) * 2011-10-19 2015-11-27 Дигнити Сайенсиз Лимитед ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ DGLA И/ИЛИ 15-HETrE, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
GB201307082D0 (en) * 2013-04-19 2013-05-29 Dignity Sciences Ltd Pharmaceutical composition comprising 15-HETrE and methods of using the same
WO2015042442A1 (en) * 2013-09-19 2015-03-26 Dignity Sciences Limited Pharmaceutical compositions comprising dha, epa, and/or gla and an antibiotic agent and methods of use thereof
ES2727387T3 (es) * 2013-11-15 2019-10-15 Ds Biopharma Ltd Sal de lisina de ácido 15-hidroxi-8(Z),11(Z),13(E)-eicosatrienoico
RU2685706C2 (ru) * 2014-01-10 2019-04-23 Эфиммьюн Лимитед Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
MX375328B (es) 2014-06-04 2025-03-06 Ds Biopharma Ltd Composiciones farmacéuticas que comprenden ácido dihomo-gamma-linolénico (dgla) y uso de las mismas
LT6177B (lt) 2014-10-10 2015-07-27 Uab "Biocentras" Fermentų kompleksų išskyrimas iš steptomyces gougerotii 101, daugiafermentinių biopreparatų ruošimas bei taikymas
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
CN107405324A (zh) * 2015-01-16 2017-11-28 艾菲穆恩有限公司 包含15‑hepe的组合物和其使用方法
CN112245420A (zh) 2015-07-21 2021-01-22 艾菲穆恩有限公司 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物
AU2016370626B2 (en) * 2015-12-18 2020-08-20 Afimmune Limited Compositions comprising 15-HEPE and methods of using the same
US20200206173A1 (en) 2017-08-30 2020-07-02 Conopco, Inc., D/B/A Unilever A personal care composition
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4344930A (en) * 1975-10-30 1982-08-17 Colgate-Palmolive Company Skin care sponge
JP4926310B2 (ja) * 1996-02-15 2012-05-09 エルテーベー4・スウェーデン・アクチェボラーグ 抗ウイルス薬および抗腫瘍薬としてのロイコトリエンb4またはその類似体の使用
US5789441A (en) * 1996-02-15 1998-08-04 Virocell Inc. Leukotriene B4 as an antiviral and anti-neoplastic agent
US6190645B1 (en) * 1999-07-15 2001-02-20 Playtex Products, Inc. Sunscreen for the scalp hair and hair
US20030073930A1 (en) * 2001-10-17 2003-04-17 Morrissey Gerald R. Methods and device for preventing or healing injured nipples or areolas in mammalian females or for obtaining samples from nipples in mammalian females
US20030105445A1 (en) * 2001-11-30 2003-06-05 Kimberly-Clark Worldwide, Inc. Breast pad assembly containing a skin benefit ingredient
WO2005102309A2 (en) * 2004-04-26 2005-11-03 Ltb4 Sweden Ab In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
JP2009522303A (ja) * 2005-12-30 2009-06-11 ウェイ−ウー ヒー, 瘢痕を生じない皮膚創傷治癒を促進するsiRNA組成物および創傷処置の方法
JP2010509930A (ja) * 2006-11-23 2010-04-02 カーギル インコーポレイテッド 化工でんぷんの天然相当物
CN101715349B (zh) * 2007-05-08 2012-07-18 美国Rq生物科技有限公司 治疗革兰氏阴性细菌感染的治疗组合物及方法
EP2159732A1 (en) * 2008-08-21 2010-03-03 Thomson Licensing Method and device for code obfuscation
GB0907413D0 (en) * 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8637298B2 (en) * 2009-06-16 2014-01-28 E I Du Pont De Nemours And Company Optimized strains of yarrowia lipolytica for high eicosapentaenoic acid production
US8293790B2 (en) * 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof

Also Published As

Publication number Publication date
US20120264705A1 (en) 2012-10-18
US20140171358A1 (en) 2014-06-19
ZA201403948B (en) 2015-12-23
AU2013211982A1 (en) 2014-06-19
BR112014018421A2 (cg-RX-API-DMAC7.html) 2017-06-20
CN104114166A (zh) 2014-10-22
MX2014006947A (es) 2015-03-05
JP6557009B2 (ja) 2019-08-07
EP2806868A4 (en) 2015-08-26
WO2013112876A1 (en) 2013-08-01
BR112014018421A8 (pt) 2017-07-11
RU2014134720A (ru) 2016-03-20
IL232777A0 (en) 2014-07-31
JP2020023513A (ja) 2020-02-13
HK1198921A1 (en) 2015-06-19
EP2806868A1 (en) 2014-12-03
KR20140117379A (ko) 2014-10-07
PH12014501693A1 (en) 2014-10-20
SG11201404088TA (en) 2014-10-30
JP2015504921A (ja) 2015-02-16
JP2018065818A (ja) 2018-04-26

Similar Documents

Publication Publication Date Title
JP6557009B2 (ja) Dgla、15−ohepaおよび/または15−hetreを含む抗菌組成物およびそれらの使用方法
US9056086B2 (en) Pharmaceutical compositions comprising DGLA, 15-HEPE, and/or 15-HETrE and methods of use thereof
US11590149B2 (en) Compositions and methods for treating acne vulgaris
US8313782B2 (en) Acne vulgaris treatment regimen
US20150094370A1 (en) Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
EA008023B1 (ru) Новые комплексы карбоксипроизводных пиридина и эфиров жирной кислоты и полигидроксиалканов
US20140057976A1 (en) Usnic acid topical formulation
US20170136086A1 (en) Topical Compositions And Methods For Treating Wounds
CN103347507A (zh) 用于治疗痤疮的褪黑激素以及抗微生物剂或抗菌剂
US20150080329A1 (en) Pharmaceutical compositions comprising dha, epa, and/or gla and an antibiotic agent and methods of use thereof
TWI329650B (en) Medicament for the treatment or prevention of acne
KR20180135169A (ko) 퀘르세틴 및 비타민 d를 함유하는 여드름 피부 개선용 조성물
CN110691591A (zh) 用于在治疗寻常痤疮中使用的希波酚
HK1074402B (en) Use of amide derivative of ge 2270 factor a3 for the treatment of acne
BR102013007895A2 (pt) formulação farmacêutica contendo b-cariofileno e uso no tratamento e profilaxia da doença periodontal canina

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180124

FZDE Discontinued

Effective date: 20210224